Profusa Swings to $28.4M Equity After $8.8M Q2 Loss, G3 Deal Progresses
PFSA has more than doubled off its 52-week low of $3.223.
Summary
Profusa reported Q2 2026 net loss of $8.8M, widening from $2.3M a year ago, but the balance sheet transformed after the G3 Vision Labs option agreement: stockholders' equity swung from a $(27.1)M deficit at June 30 to an expected $28.4M by July 31. Debt holders have executed $10.7M of Series A Convertible Exchange Agreements, with $4.57M already converted into preferred stock, and the company borrowed $650,000 for near-term working capital. The 4:1 reverse split effective August 18 helped meet Nasdaq minimum listing requirements. G3's audited 2024 and 2025 financials are expected by mid-September, a key condition to closing the acquisition. This follows the 10-Q filed yesterday that detailed the same loss and going concern doubts, but today's release adds the equity swing, exchange agreement progress, and audit timeline—material new information for traders assessing the deal's viability.
At the time of this announcement, PFSA was trading at $13.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $3.22 to $5,190.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.